Malignant Mesothelioma Treatment Market -The growing use of asbestos for commercial purposes.

Malignant mesothelioma is a deadly and rare type of cancer that affects the mesothelium, a membrane forming a thin lining of the body's internal organs (pleurae, peritoneum, and pericardium). The mesothelium allows a special lubricating fluid which helps protect the organs and enables organs to push against each other. Some main symptoms include shortness of breath, pain in the chest and cough. For the signs to manifest it takes between 35 to 50 years.

The global market for malignant mesothelioma therapy is expected to report a CAGR of nearly 7.5% in the 2020-2027 period.

The growing use of asbestos for commercial purposes is a key factor driving the growth of the global malignant mesothelioma therapeutics market size. Asbestos toxicity is the prime risk factor for malignant mesothelioma. Asbestos use has increased dramatically over the years in various applications such as machinery, construction materials, and automobiles for transportation. Thus, the widespread use of asbestos for commercial purposes during the forecast period will boost the global demand for malignant mesothelioma therapies. The increasing understanding of malignant mesothelioma would have a positive impact on the market and significantly contribute to its growth over the forecast period.
Most companies on the global malignant mesothelioma market focus on collaborating with organizations to study multiple drug combinations on malignant mesotheliome. Since there are very few companies that have patents for procedures, many companies conduct clinical trials that focus on various combination drugs. Boehringer Ingelheim, for example, entered phase 3 in 2017 for its double-blind, randomized, phase 3 trial of Nintedanib in combination with Pemetrexed / Cisplatin followed by continued monotherapy of Nintedanib versus placebo in combination with Pemetrexed / Cisplatin followed by continued placebo monotherapy for mesothelioma diagnosis.

Segment route of administration for the market in the treatment of mesothelioma is categorized into oral, parenteral, and other. The market for mesothelioma treatment is segmented into hospitals, homecare, specialty clinics and others, based on end-users. The market for mesothelioma treatment was divided into hospital pharmacy, online pharmacy, and retail pharmacy based on distribution channel.

Pemetrexed and combination segment is the largest drug-type segment on the global malignant mesothelioma market, projected to account for close to US$ 160 million, or more than 45 percent of the overall market share in 2017, and more than US$ 300 million by the end of the 2017-2025 forecast period, growing to CAGR by 8.4 percent. The segment Pemetrexed and Combination is expected to gain more than 300 BPS in market share in 2025 over 2017 due to its improved response rate of around 30 percent -40 percent when used individually or in combination with other medicines. In 2016, the pemetrexed and combination drug type segment dominated the global market for malignant mesothelioma in terms of revenue, and the trend is projected to grow over the forecast period. Also the most attractive segment is the Pemetrexed and Combination segment, recording a 3.2 market attractiveness index over the forecast period.